Inventor · disambiguated record
Thomas Engelbrecht Nordkild Jonassen
Also filed as: JONASSEN THOMAS ENGELBRECHT NORDKILD · JONASSEN THOMAS ENGELBRECHT NORKILD
3 granted patents·12 pending applications·3 citations·filing 2007–2025
57Inventor score
Top patents by PatentIndex Score
15 records- 0181US12239631B2Polymorphs of phenyl pyrrole aminoguandium saltsSYNACT PHARMA APS·Filed 2024·Granted Mar 4, 2025·1 cites·27 claims
- 0273US12303489B2Combination treatment of arthritic diseaseSYNACT PHARMA APS·Filed 2020·Granted May 20, 2025·1 cites·18 claims
- 0369US2023114865A1Phenyl pyrrole aminoguanidine salts and formulationsSYNACT PHARMA APS·Filed 2022·Application pending·0 cites
- 0464US8058306B2Phenyl pyrrole aminoguanidine derivativesBOMAN ARNE·Filed 2007·Granted Nov 15, 2011·1 cites·29 claims
- 0561US2023271922A9Polymorphs of phenyl pyrrole aminoguandium saltsSYNACT PHARMA APS·Filed 2022·Application pending·0 cites
- 0655US2025387365A1Combination Treatment Of Arthritic DiseaseSYNACT PHARMA APS·Filed 2025·Application pending·0 cites
- 0754US2025345392A1Annexin a1 liquid pharmaceutical compositionRESOTHER PHARMA AS·Filed 2023·Application pending·0 cites
- 0852US2023295255A1Annexin a1-derived polypeptide analoguesRESO THER PHARMA AS·Filed 2021·Application pending·0 cites
- 0952US2025388632A1Annexin a1-derived polypeptide analoguesRESOTHER PHARMA AS·Filed 2023·Application pending·0 cites
- 1051US2023303640A1Exendin-4 peptide analogsTXP PHARMA AG·Filed 2021·Application pending·0 cites
- 1151US2014121164A1Prevention of kidney injury or diseaseUNIV FLORIDA·Filed 2013·Application pending·0 cites
- 1251US2025302804A1Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosisSYNACT PHARMA APS·Filed 2023·Application pending·0 cites
- 1351US2025032449A1Treatment of rheumatoid arthritisSYNACT PHARMA APS·Filed 2022·Application pending·0 cites
- 1443US2023149351A1Treatment of symptomatic viral diseasesSYNACT PHARMA APS·Filed 2021·Application pending·0 cites
- 1543US2021121418A1Treatment of proteinuriaSYNACT PHARMA APS·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →